192 related articles for article (PubMed ID: 26744530)
21. Nonspecific Inhibition of IL6 Family Cytokine Signalling by Soluble gp130.
Widjaja AA; Cook SA
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338642
[TBL] [Abstract][Full Text] [Related]
22. Kras(G12D) and Nkx2-1 haploinsufficiency induce mucinous adenocarcinoma of the lung.
Maeda Y; Tsuchiya T; Hao H; Tompkins DH; Xu Y; Mucenski ML; Du L; Keiser AR; Fukazawa T; Naomoto Y; Nagayasu T; Whitsett JA
J Clin Invest; 2012 Dec; 122(12):4388-400. PubMed ID: 23143308
[TBL] [Abstract][Full Text] [Related]
23. A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma.
Yamaguchi T; Ikehara S; Nakanishi H; Ikehara Y
J Pathol; 2014 Oct; 234(2):228-38. PubMed ID: 25042889
[TBL] [Abstract][Full Text] [Related]
24. Modeling K-Ras-driven lung adenocarcinoma in mice: preclinical validation of therapeutic targets.
Drosten M; Barbacid M
J Mol Med (Berl); 2016 Feb; 94(2):121-35. PubMed ID: 26526121
[TBL] [Abstract][Full Text] [Related]
25. Ezh2 Acts as a Tumor Suppressor in Kras-driven Lung Adenocarcinoma.
Wang Y; Hou N; Cheng X; Zhang J; Tan X; Zhang C; Tang Y; Teng Y; Yang X
Int J Biol Sci; 2017; 13(5):652-659. PubMed ID: 28539837
[TBL] [Abstract][Full Text] [Related]
26. IL-6 trans-signaling modulates TLR4-dependent inflammatory responses via STAT3.
Greenhill CJ; Rose-John S; Lissilaa R; Ferlin W; Ernst M; Hertzog PJ; Mansell A; Jenkins BJ
J Immunol; 2011 Jan; 186(2):1199-208. PubMed ID: 21148800
[TBL] [Abstract][Full Text] [Related]
27. MicroRNA-31 initiates lung tumorigenesis and promotes mutant KRAS-driven lung cancer.
Edmonds MD; Boyd KL; Moyo T; Mitra R; Duszynski R; Arrate MP; Chen X; Zhao Z; Blackwell TS; Andl T; Eischen CM
J Clin Invest; 2016 Jan; 126(1):349-64. PubMed ID: 26657862
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade.
Akbay EA; Koyama S; Liu Y; Dries R; Bufe LE; Silkes M; Alam MM; Magee DM; Jones R; Jinushi M; Kulkarni M; Carretero J; Wang X; Warner-Hatten T; Cavanaugh JD; Osa A; Kumanogoh A; Freeman GJ; Awad MM; Christiani DC; Bueno R; Hammerman PS; Dranoff G; Wong KK
J Thorac Oncol; 2017 Aug; 12(8):1268-1279. PubMed ID: 28483607
[TBL] [Abstract][Full Text] [Related]
29. Pivotal Role of the Chromatin Protein Nupr1 in Kras-Induced Senescence and Transformation.
Grasso D; Bintz J; Lomberk G; Molejon MI; Loncle C; Garcia MN; Lopez MB; Urrutia R; Iovanna JL
Sci Rep; 2015 Nov; 5():17549. PubMed ID: 26617245
[TBL] [Abstract][Full Text] [Related]
30. Soluble IL6R Expressed by Myeloid Cells Reduces Tumor-Specific Th1 Differentiation and Drives Tumor Progression.
Tsukamoto H; Fujieda K; Hirayama M; Ikeda T; Yuno A; Matsumura K; Fukuma D; Araki K; Mizuta H; Nakayama H; Senju S; Nishimura Y
Cancer Res; 2017 May; 77(9):2279-2291. PubMed ID: 28235765
[TBL] [Abstract][Full Text] [Related]
31. Mutant KRAS Downregulates the Receptor for Leukemia Inhibitory Factor (LIF) to Enhance a Signature of Glycolysis in Pancreatic Cancer and Lung Cancer.
Liu S; Gandler HI; Tošić I; Ye DQ; Giaccone ZT; Frank DA
Mol Cancer Res; 2021 Aug; 19(8):1283-1295. PubMed ID: 33931487
[TBL] [Abstract][Full Text] [Related]
32. Synergistic function of Kras mutation and HBx in initiation and progression of hepatocellular carcinoma in mice.
Ye H; Zhang C; Wang BJ; Tan XH; Zhang WP; Teng Y; Yang X
Oncogene; 2014 Oct; 33(43):5133-8. PubMed ID: 24213574
[TBL] [Abstract][Full Text] [Related]
33. Protein Kinase Cι Drives a NOTCH3-dependent Stem-like Phenotype in Mutant KRAS Lung Adenocarcinoma.
Ali SA; Justilien V; Jamieson L; Murray NR; Fields AP
Cancer Cell; 2016 Mar; 29(3):367-378. PubMed ID: 26977885
[TBL] [Abstract][Full Text] [Related]
34. A single extra copy of Dscr1 improves survival of mice developing spontaneous lung tumors through suppression of tumor angiogenesis.
Shin J; Lee JC; Baek KH
Cancer Lett; 2014 Jan; 342(1):70-81. PubMed ID: 24051307
[TBL] [Abstract][Full Text] [Related]
35. Context-Dependent Effects of Amplified MAPK Signaling during Lung Adenocarcinoma Initiation and Progression.
Cicchini M; Buza EL; Sagal KM; Gudiel AA; Durham AC; Feldser DM
Cell Rep; 2017 Feb; 18(8):1958-1969. PubMed ID: 28228261
[TBL] [Abstract][Full Text] [Related]
36. UHRF1 is a mediator of KRAS driven oncogenesis in lung adenocarcinoma.
Kostyrko K; Román M; Lee AG; Simpson DR; Dinh PT; Leung SG; Marini KD; Kelly MR; Broyde J; Califano A; Jackson PK; Sweet-Cordero EA
Nat Commun; 2023 Jul; 14(1):3966. PubMed ID: 37407562
[TBL] [Abstract][Full Text] [Related]
37. DNA vaccine elicits an efficient antitumor response by targeting the mutant Kras in a transgenic mouse lung cancer model.
Weng TY; Yen MC; Huang CT; Hung JJ; Chen YL; Chen WC; Wang CY; Chang JY; Lai MD
Gene Ther; 2014 Oct; 21(10):888-96. PubMed ID: 25077772
[TBL] [Abstract][Full Text] [Related]
38. STAT3 is a master regulator of epithelial identity and KRAS-driven tumorigenesis.
D'Amico S; Shi J; Martin BL; Crawford HC; Petrenko O; Reich NC
Genes Dev; 2018 Sep; 32(17-18):1175-1187. PubMed ID: 30135074
[TBL] [Abstract][Full Text] [Related]
39. Critical requirement of SOS1 for tumor development and microenvironment modulation in KRAS
Baltanás FC; García-Navas R; Rodríguez-Ramos P; Calzada N; Cuesta C; Borrajo J; Fuentes-Mateos R; Olarte-San Juan A; Vidaña N; Castellano E; Santos E
Nat Commun; 2023 Sep; 14(1):5856. PubMed ID: 37730692
[TBL] [Abstract][Full Text] [Related]
40. AGO2 promotes tumor progression in KRAS-driven mouse models of non-small cell lung cancer.
Tien JC; Chugh S; Goodrum AE; Cheng Y; Mannan R; Zhang Y; Wang L; Dommeti VL; Wang X; Xu A; Hon J; Kenum C; Su F; Wang R; Cao X; Shankar S; Chinnaiyan AM
Proc Natl Acad Sci U S A; 2021 May; 118(20):. PubMed ID: 33972443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
